Chordate granted new patent by the European Patent Office

Chordate Medical Holding AB (publ) (“Chordate”, the “Company”) announces that the European Patent Office intends to grant Chordate’s patent application EP 17168265.1 from 2017. The patent application relates to further development of the Company’s treatment technology for primarily chronic migraine, Kinetic Oscillation Stimulation, K.O.S.

“The aim of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company’s intellectual property enables exclusivity in the market, which is a cornerstone of the shareholder value the company is building”, says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical holds approximately 71 patents across 26 countries and 9 patent families, covering various aspects of the company’s treatment technologies. The granting of application EP 17168265.1 adds further patents to a growing portfolio that the company started to build in 2008.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy